Testing butylphthalide for multiple system atrophy
Part of Brain & nervous system clinical trials.
This study tests whether a drug called butylphthalide can safely help people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions like blood pressure. Participating may help slow the progression of symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of multiple system atrophy (MSA) by a neurologist.
- You are between 30 and 80 years old and were diagnosed within the last 5 years.
- You are still able to walk or move around (not fully dependent on a wheelchair or bedridden).
- You have been on a stable medication plan for at least one month before the trial.
- You do not have other major neurological diseases, severe liver or kidney problems, recent bleeding risks, severe memory loss, cancer, or certain psychiatric conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This trial tests a new stem cell treatment for people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions. The treatment uses stem cells from healthy donors, which may help slow down the disease.
This trial tests a new antibody therapy that may target and remove abnormal proteins in the brain linked to Multiple System Atrophy (MSA). It aims to see if the treatment is safe and whether it can help slow the progression of the disease.
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
This study is collecting information from patients with multiple system atrophy (a rare neurological condition affecting movement and body functions), Parkinson disease, and healthy volunteers to better understand these conditions. By participating, you help doctors learn more about how these diseases develop and progress.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.